https://orcid.org/0000-0003-1009-2247
References
- André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.
- Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
- Engelhardt BG, Holland DW, Brandt SJ, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk Lymphoma. 2007;48(9):1728–1735.
- Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
- Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
- Chen R, Zinzani PL, Fanale MA, et al.; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
- Connors JM, Jurczak W, Straus DJ, et al.; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344.
- Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–460.
- Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18(13):2615–2619.
- Stadtmauer EA, Cassileth PA, Gale RP. Etoposide in leukemia, lymphoma and bone marrow transplantation. Leuk Res. 1989;13(8):639–650.
- Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol. 1994;5(9):817–820.
- Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood. 2018;131(15):1698–1703.
- Hansen HH, Selawry OS, Pajak TF, et al. The superiority of CCNU in the treatment of advanced Hodgkin’s disease: Cancer and Leukemia Group B Study. Cancer. 1981;47(1):14–18.
- Proctor SJ, Lennard AL, Jackson GH, et al. The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control. Ann Oncol. 2010;21(2):426–428.
- Vasanthamohan L, Parker B, Mangel J, et al. The use of CEP (lomustine, etoposide and prednisone), an all-oral palliative chemotherapy regimen, in aggressive lymphomas. Blood. 2019;134(Supplement_1):4131.